Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection

AIDS

Volumn 12, Issue 9, 1998, Pages

  Van Rompay, Koen K A ^a   Berardi, Christopher J ^a   Aguirre, Nancy L ^a   Bischofberger, Norbert ^b   Lietman, Paul S ^c   Pedersen, Niels C ^a,d   Marthas, Marta L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GILEAD SCIENCES   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

9 2 (phosphonomethoxy)propyl adenine; Animal model; Pediatrics; Prevention; Primate; Prophylaxis; Simian immunodeficiency virus; Vertical transmission

Indexed keywords

ADENINE DERIVATIVE; TENOFOVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; MACACA; NEWBORN; NEWBORN INFECTION; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS INFECTION;

EID: 0032543742     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199809000-00001     Document Type: Article

References (22)

1. UNAIDS/WHO: Report on the the Global HIV/AIDS Epidemic. Geneva: UNAIDS; December 1997.
2. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
3. Centers for Disease Control and Prevention: Update: perinatally acquired HIV/AIDS - United States, 1997. MMWR 1997, 46:1086-1092.
4. Centers for Disease Control and Prevention: Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission - Thailand, 1996-1998. MMWR 1998, 47:151-154.
5. Mofenson LM: Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr Suppl 1997, 421:1-9.
6. Van Rompay KKA, Otsyula MG, Tarara RP, et al.: Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection. J Infect Dis 1996, 173:1327-1335.
7. Baba TW, Koch J, Mittler ES, et al.: Mucosal infection of neonatal rhesus monkeys with cell-free SIV. AIDS Res Hum Retroviruses 1994, 10:351-357.
8. Van Rompay KKA, Marthas ML, Ramos RA, et al.: Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimocrob Agents Chemother 1992, 36:2381-2386.
9. Van Rompay KKA, Otsyula MG, Marthas ML, Miller CJ, McChesney MB, Pedersen NC: Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother 1995, 39:125-131.
10. Van Rompay KKA, Berardi CJ, Dillard-Telm S, et al.: Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 1998, 177:1247-1259.
11. Van Rompay KKA, Marthas ML, Lifson JD, et al.: Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses 1998, 14:761-773.
12. Tsai C-C, Follis KE, Beck TW, et al.: Prevention of simian immunodeficiency virus infection in macaques by 9-(2-phosphonylmethoxypropyl)adenine (PMPA). Science 1995, 270:1197-1199.
13. Committee on Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
14. Van Rompay KKA, Cherrington JM, Marthas ML, et al.: 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemolher 1996, 40:2586-2591.
15. mac251. AIDS 1998, 12:1-10.
16. Otsyula MG, Miller CJ, Marthas ML, et al.: Virus-induced immunosuppression is linked to rapidly fatal disease in infant rhesus macaques infected with simian immunodeficiency virus. Pediatr Res 1996, 39:630-635.
17. Blark RJ: Animal studies of prophylaxis. Am J Med 1997, 102 (5B):39-43.
18. Shirasaka T, Chokekijchai S, Yamada A, Gosselin G, Imbach J-L, Mitsuya H: Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob Agents Chemother 1995, 39:2555-2559.
19. Perno CF, Balestra E, Aquaro S, et al.: Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines. Mol Pharmarol 1996, 50:359-366.
20. Balzarini J, Hao Z, Herdewijn P, Johns DG, De Clercq E: Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci USA 1991, 88:1499-1503.
21. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A: Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998, 42:612-617.
22. Tarantal AF, Bischofberger N, Marthas ML: Administration of PMPA to gravid macaques. 14th Annual Symposium on Nonhuman Primate Models for AIDS. Portland, October 1996 [abstract 110].